Brought to you by 
Opiant gets exclusive rights to Sanofi's edibles overdose remedy
09 Aug 2019
Executive Summary
Sanofi granted Opiant Pharmaceuticals Inc. exclusive global rights to develop and commercialize the cannabinoid CB-1 receptor antagonist drinabant, which Opiant will develop as an injectable overdose remedy for use in the emergency room setting.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Opiant gets exclusive rights to Sanofi's edibles overdose remedy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice